复宏汉霖(02696)：HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药

智通财经08-08

智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX53(抗TIGIT的Fc融合蛋白)(HLX53)联合汉斯状® (斯鲁利单抗注射液)(汉斯状®)及汉贝泰® (贝伐珠单抗注射液)(汉贝泰®)一线治疗局部晚期或转移性肝细胞癌(HCC)的2 期临床研究于中国境内(不包括港澳台地区，下同)完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状®及汉贝泰®...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2457439835?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-08 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457439835","market":"sh","top_or_hot":-1,"title":"复宏汉霖(02696)：HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX53(抗TIGIT的Fc融合蛋白)(HLX53)联合汉斯状® (斯鲁利单抗注射液)(汉斯状®)及汉贝泰® (贝伐珠单抗注射液)(汉贝泰®)一线治疗局部晚期或转移性肝细胞癌(HCC)的2 期临床研究于中国境内(不包括港澳台地区，下同)完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状®及汉贝泰®...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1161746.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复宏汉霖(02696)：HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复宏汉霖(02696)：HLX53联合汉斯状®及汉贝泰®一线治疗局部晚期或转移性肝细胞癌的2期临床研究于中国境内完成首例患者给药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-08 18:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1161746.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX53(抗TIGIT的Fc融合蛋白)(HLX53)联合汉斯状® (斯鲁利单抗注射液)(汉斯状®)及汉贝泰® (贝伐珠单抗注射液)(汉贝泰®)一线治疗局部晚期或转移性肝细胞癌(HCC)的2 期临床研究于中国境内(不包括港澳台地区，下同)完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状®及汉贝泰®...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1161746.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1161746.html","article_id":"2457439835","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457439835","pubTimestamp":1723113201,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复宏汉霖 发布公告，近日，HLX53联合汉斯状 (汉斯状)及汉贝泰 (汉贝泰)一线治疗局部晚期或转移性肝细胞癌的2 期临床研究于中国境内完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状及汉贝泰对比安慰剂联合汉斯状及汉贝泰在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖"},"translate_title":"Henlius (02696): Phase 2 clinical study of HLX53 combined with Hans-like ® and Hanbetai ® in the first-line treatment of locally advanced or metastatic hepatocellular carcinoma completed the first patient administration in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，HLX53(抗TIGIT的Fc融合蛋白)(HLX53)联合汉斯状® (斯鲁利单抗注射液)(汉斯状®)及汉贝泰® (贝伐珠单抗注射液)(汉贝泰®)一线治疗局部晚期或转移性肝细胞癌(HCC)的2 期临床研究于中国境内(不包括港澳台地区，下同)完成首例患者给药。本研究为一项随机、双盲、多中心的2期临床研究，旨在评估HLX53联合汉斯状®及汉贝泰®对比安慰剂联合汉斯状®及汉贝泰®在未经治疗的局部晚期或转移性肝细胞癌患者中的有效性、安全性和耐受性。研究分为两个部分： A部分为安全导入期，将采用“3+3”剂量递增设计，合格的受试者将接受每三周一次静脉输注不同剂量HLX53(1000 mg或2000 mg)联合汉斯状®(300 mg)及汉贝泰®(15 mg/kg)的治疗;B部分为初步疗效探索期，合格的受试者将按照1:1:1的比例，随机分配接受每三周一次静脉输注HLX53(1000 mg)、 HLX53(2000 mg)或安慰剂分别联合汉斯状®(300 mg)及汉贝泰®(15 mg/kg)的治疗。A部分的主要终点为安全性和耐受性，评估每个剂量组中发生剂量限制毒性(DLT)事件的患者比例。B部分的主要终点为由独立影像评估委员会根据RECIST v1.1评估的客观缓解率和无进展生存期。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457439835"}